VA/DoD CLINICAL PRACTICE GUIDELINE FOR OPIOID THERAPY FOR CHRONIC PAIN

Recommendations

Info

DRAFT 3 - DO NOT DISTRIBUTE VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain 165. Zedler B, Xie L, Wang L, et al. Development of a risk index for serious prescription opioid-induced respiratory depression or overdose in Veterans' Health Administration patients. Pain Med. Aug 2015;16(8):1566-1579. 166. Ray WA, Chung CP, Murray KT, Cooper WO, Hall K, Stein CM. Out-of-hospital mortality among patients receiving methadone for noncancer pain. JAMA Intern Med. Mar 2015;175(3):420-427. 167. Hartung DM, Middleton L, Haxby DG, Koder M, Ketchum KL, Chou R. Rates of adverse events of long-acting opioids in a state medicaid program. Ann Pharmacother. Jun 2007;41(6):921-928. 168. Krebs EE, Becker WC, Zerzan J, Bair MJ, McCoy K, Hui S. Comparative mortality among Department of Veterans Affairs patients prescribed methadone or long-acting morphine for chronic pain. Pain. Aug 2011;152(8):1789-1795. 169. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: A clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain. Apr 2014;15(4):321-337. 170. Murphy JL, Clark ME, Banou E. Opioid cessation and multidimensional outcomes after interdisciplinary chronic pain treatment. Clin J Pain. Feb 2013;29(2):109-117. 171. Townsend CO, Kerkvliet JL, Bruce BK, et al. A longitudinal study of the efficacy of a comprehensive pain rehabilitation program with opioid withdrawal: Comparison of treatment outcomes based on opioid use status at admission. Pain. Nov 15 2008;140(1):177-189. 172. Berna C, Kulich RJ, Rathmell JP. Tapering long-term opioid therapy in chronic noncancer pain: Evidence and recommendations for everyday practice. Mayo Clin Proc. Jun 2015;90(6):828-842. 173. Kral LA, Jackson K, Uritsky TJ. A practical guide to tapering opioids. Mental Health Clinician. 2015;5(3):102-108. 174. Substance Abuse and Mental Health Services Administration. Substance abuse treatment advisory. 2010; http://store.samhsa.gov/shin/content/SMA10-4554/SMA10-4554.pdf. 175. Kahan M, Wilson L, Mailis-Gagnon A, Srivastava A. Canadian guideline for safe and effective use of opioids for chronic noncancer pain: Clinical summary for family physicians. Part 2: Special populations. Can Fam Physician. Nov 2011;57(11):1269-1276, e1419-1228. 176. Meghani SH, Wiedemer NL, Becker WC, Gracely EJ, Gallagher RM. Predictors of resolution of aberrant drug behavior in chronic pain patients treated in a structured opioid risk management program. Pain Med. Jul-Aug 2009;10(5):858-865. 177. Volkow ND, Li TK. Drug addiction: The neurobiology of behaviour gone awry. Nat Rev Neurosci. Dec 2004;5(12):963-970. 178. Hser YI, Evans E, Grella C, Ling W, Anglin D. Long-term course of opioid addiction. Harv Rev Psychiatry. Mar-Apr 2015;23(2):76-89. 179. Moore BA, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: Comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. Apr 2007;22(4):527-530. 180. Sigmon SC. Characterizing the emerging population of prescription opioid abusers. Am J Addict. May-Jun 2006;15(3):208-212. 181. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: A 2-phase randomized controlled trial. Arch Gen Psychiatry. Dec 2011;68(12):1238-1246. 182. Dennis BB, Bawor M, Naji L, et al. Impact of chronic pain on treatment prognosis for patients with opioid use disorder: A systematic review and meta-analysis. Subst Abuse. 2015;9:59-80. 183. Sun EC, Darnall BD, Baker LC, Mackey S. Incidence of and risk factors for chronic opioid use among opioid-naive patients in the postoperative period. JAMA Intern Med. Sep 01 2016;176(9):1286- 1293. February 2017 Page 188 of 192
DRAFT 3 - DO NOT DISTRIBUTE VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain 184. Halbert BT, Davis RB, Wee CC. Disproportionate longer-term opioid use among U.S. Adults with mood disorders. Pain. Nov 2016;157(11):2452-2457. 185. Deyo RA, Hallvik SE, Hildebran C, et al. Association between initial opioid prescribing patterns and subsequent long-term use among opioid-naive patients: A statewide retrospective cohort study. J Gen Intern Med. Jan 2017;32(1):21-27. 186. Inacio MC, Hansen C, Pratt NL, Graves SE, Roughead EE. Risk factors for persistent and new chronic opioid use in patients undergoing total hip arthroplasty: A retrospective cohort study. BMJ Open. Apr 29 2016;6(4):e010664. 187. Goesling J, Moser SE, Zaidi B, et al. Trends and predictors of opioid use after total knee and total hip arthroplasty. Pain. Jun 2016;157(6):1259-1265. 188. Liang Y, Turner BJ. Assessing risk for drug overdose in a national cohort: Role for both daily and total opioid dose? J Pain. Apr 2015;16(4):318-325. 189. Standridge JB, Adams SM, Zotos AP. Urine drug screening: A valuable office procedure. Am Fam Physician. Mar 1 2010;81(5):635-640. 190. Moeller KE, Lee KC, Kissack JC. Urine drug screening: Practical guide for clinicians. Mayo Clin Proc. Jan 2008;83(1):66-76. 191. PharmaCom Group, Inc. Urine drug testing in clinical practice. 5th ed. 2012; http://www.pharmacomgroup.com/udt/udt5.pdf. 192. Vincent EC, Zebelman A, Goodwin C, Stephens MM. Clinical inquiries. What common substances can cause false positives on urine screens for drugs of abuse? J Fam Pract. Oct 2006;55(10):893- 894, 897. 193. Woelfel J. Drug abuse urine tests: False-positive results. Pharmacist’s Letter/Prescriber’s Letter. 2005;21(3):210314. 194. Brahm NC, Yeager LL, Fox MD, Farmer KC, Palmer TA. Commonly prescribed medications and potential false-positive urine drug screens. Am J Health Syst Pharm. Aug 15 2010;67(16):1344- 1350. 195. Verstraete AG. Detection times of drugs of abuse in blood, urine, and oral fluid. Ther Drug Monit. Apr 2004;26(2):200-205. 196. Interagency guideline on opioid dosing for chronic non-cancer pain: An educational aid to improve care and safety with opioid therapy 2010 update. http://www.agencymeddirectors.wa.gov/Files/OpioidGdline.pdf. Accessed June 14, 2016. 197. U.S. Department of Veterans Affairs. VA Academic Detailing Service. Opioid use disorder: A VA clinician's guide to identification and management of opioid use disorder 2016; http://www.pbm.va.gov/PBM/AcademicDetailingService/Documents/Opioid_Use_Disorder_Educ ational_Guide.pdf. Accessed January 18, 2017. 198. UpToDate. Wolters Kluwer. http://www.uptodate.com. Accessed September, 2016. 199. Ripamonti C, Zecca E, Bruera E. An update on the clinical use of methadone for cancer pain. Pain. Apr 1997;70(2-3):109-115. 200. Garrido MJ, Troconiz IF. Methadone: A review of its pharmacokinetic/pharmacodynamic properties. J Pharmacol Toxicol Methods. Oct 1999;42(2):61-66. 201. Wolff K, Rostami-Hodjegan A, Shires S, et al. The pharmacokinetics of methadone in healthy subjects and opiate users. Br J Clin Pharmacol. Oct 1997;44(4):325-334. 202. Olsen GD, Wendel HA, Livermore JD, Leger RM, Lynn RK, Gerber N. Clinical effects and pharmacokinetics of racemic methadone and its optical isomers. Clin Pharmacol Ther. Feb 1977;21(2):147-157. 203. Verebely K, Volavka J, Mule S, Resnick R. Methadone in man: Pharmacokinetic and excretion studies in acute and chronic treatment. Clin Pharmacol Ther. Aug 1975;18(2):180-190. February 2017 Page 189 of 192
Page 1 and 2:
VA/DoD CLINICAL PRACTICE GUIDELINE
Page 3 and 4:
VA/DoD Clinical Practice Guideline
Page 5 and 6:
Page 7 and 8:
Page 9 and 10:
Page 11 and 12:
Page 13 and 14:
Page 15 and 16:
Page 17 and 18:
Page 19 and 20:
Page 21 and 22:
Page 23 and 24:
Page 25 and 26:
Page 27 and 28:
Page 29 and 30:
Page 31 and 32:
Page 33 and 34:
Page 35 and 36:
Page 37 and 38:
Page 39 and 40:
Page 41 and 42:
Page 43 and 44:
Page 45 and 46:
Page 47 and 48:
Page 49 and 50:
Page 51 and 52:
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
Page 59 and 60:
Page 61 and 62:
Page 63 and 64:
Page 65 and 66:
Page 67 and 68:
Page 69 and 70:
Page 71 and 72:
Page 73 and 74:
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
Page 81 and 82:
Appendix D: Drug Tables A. Short-ac
Page 83 and 84:
Short-Acting Opioid Initial Oral Do
Page 85 and 86:
Short-Acting Opioid Initial Oral Do
Page 87 and 88:
Short-Acting Opioid Tramadol (alone
Page 89 and 90:
Long-Acting/ER Opioids 1 Buprenorph
Page 91 and 92:
Long-Acting/ER Opioids 1 Hydrocodon
Page 93 and 94:
Long-Acting/ER Opioids 1 Initial Do
Page 95 and 96:
Page 97 and 98:
Page 99 and 100:
3 CYP-3A4 inhibiting agents include
Page 101 and 102:
Page 103 and 104:
Page 105 and 106:
Page 107 and 108:
Page 109 and 110:
Page 111 and 112:
Page 113 and 114:
Page 115 and 116:
Page 117 and 118:
Page 119 and 120:
Page 121 and 122:
Page 123 and 124:
Page 125 and 126:
Page 127 and 128:
Page 129 and 130:
Page 131 and 132:
Page 133 and 134:
Page 135 and 136:
Page 137 and 138: VA/DoD Clinical Practice Guideline
Page 163 and 164: DRAFT 3 - DO NOT DISTRIBUTE VA/DoD
Page 187: DRAFT 3 - DO NOT DISTRIBUTE VA/DoD
show all

VA/DoD CLINICAL PRACTICE GUIDELINE FOR OPIOID THERAPY FOR CHRONIC PAIN

Create successful ePaper yourself

Delete template?

Save as template?